Prevalence of coronary artery disease in chronic obstructive pulmonary disease patients- a retrospective observational study
DOI:
https://doi.org/10.18203/2394-6040.ijcmph20234138Keywords:
COPD, CAD, HT, InflammationAbstract
Background: Chronic obstructive pulmonary disease (COPD) is characterized by chronic inflammation that results in progressive and irreversible air flow obstruction usually caused by an inflammatory response of the lungs to noxious particles and gases. There are periods of acute episodes of worsening and exacerbation. COPD was predicted to be the third leading cause of death worldwide by 2020, is a major cause of disability adjusted life years (DALY). Patients with COPD are often complicated by coronary artery disease (CAD), both of which are public health problems. There are probably a lot of mechanisms involved in the co-existence of these comorbidities like ageing, sedentary life style, systemic inflammation, atherosis and arterial stiffness. The confirmation of this comorbidity in COPD is very important as it can have implications in the management of the disease.
Methods: This observational study was done in a tertiary care hospital in Central Kerala. It was a retrospective observational study. 100 patients were included in the study.
Results: Out of 100 COPD patients that were included in the study, 27% of them had CAD as a comorbidity which implies that all patients with COPD should be screened for CAD as well.
Conclusions: All COPD patients should be screened for a coexisting CAD.
Metrics
References
Vestbo J, Hurd SS, Agustí AG, Jones PW, Vogelmeier C, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2012;187:347-65.
Mannino DM, Buist AS. Global burden of COPD: risk factors, prevalence, and future trends. Lancet. 2007;370:765-73.
Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. New Engl J Med. 2005;352:1685-95.
Libby P, Tabas I, Fredman G, Fisher EA. Inflammation and its resolution as determinants of acute coronary syndromes. Circ Res. 2014;114:1867-79.
Finkelstein J, Cha E, Scharf SM. Chronic obstructive pulmonary disease as an independent risk factor for cardiovascular morbidity. Int J Chron Obstruct Pulm Dis. 2009;4:337-49.
Mannino DM, Thorn D, Swensen A, Holguin F. Prevalence and outcomes of diabetes, hypertension and cardiovascular disease in COPD. Eur Respir J. 2008;32:962-9.
Gupta R. Burden of coronary heart disease in India. Indian Heart J. 2005,57:632-8.
Ghaffar A, Reddy KS, Singhi M. Burden of non-communicable diseases in South Asia. Br Med J. 2004;328:807-10.
Divo M, Cote C, de Torres JP, Casanova C, Marin JM, Pinto-Plata V, et al. Comorbidities and risk of mortality in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2012;186:155-61.
Smith MC, Wrobel JP. Epidemiology and clinical impact of major comorbidities in patients with COPD. Int J Chron Obstruct Pulmon Dis. 2014;9:871-88.
van den Akker M, Buntinx F, Knottnerus JA. Comorbidity or multimorbidity: what's in a name? A review of literature. Eur J Gen Pract. 1996;2:65-70.
Iftikhar IH, Imtiaz M, Brett AS, Amrol DJ. Cardiovascular safety of long acting beta agonist-inhaled corticosteroid combination products in adult patients with asthma: a systematic review. Lung. 2014;192:47-54.
Salpeter SR, Ormiston TM, Salpeter EE. Cardiovascular effects of β-agonists in patients with asthma and COPD: a meta-analysis. Chest. 2004;125:2309-21.
Gershon A, Croxford R, Calzavara A, To T, Stanbrook MB, Upshur R, et al. Cardiovascular safety of inhaled long-acting bronchodilators in individuals with chronic obstructive pulmonary disease. JAMA Intern Med. 2013;173:1175-85.
Downloads
Published
How to Cite
Issue
Section
